December 15, 2025
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
– Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in Gout– Acquisition
October 14, 2025
Arthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous Gout
Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN
August 21, 2025
Arthrosi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
— Enrollment completed well ahead of schedule; both Phase 3 trials now fully enrolled with data expected
关于我们
Arthrosi Therapeutics 是一家临床阶段的生物技术公司,专注于开发痛风和慢性肾脏疾病的治疗方法。我们的专利候选药物 AR882在患有不同程度肾功能损害的痛风患者中表现出前所未有的持续降低尿酸,显示出治疗痛风和痛风石的所有阶段的潜力。
Arthrosi 致力于……
- 创建一个以人为本的环境——您是我们所做的一切和我们所做的每一个决定的中心。
- 成为您的健康伙伴——我们致力于为痛风患者带来更好的生活质量。
美国痛风患者
痛风发作
痛风石
慢性难治痛风患者
900 万痛风患者中有很大一部分未得到充分治疗,他们依赖于不能满足他们需求的短期或次优治疗。我们的使命是通过痛风治疗的新时代消除痛风的痛苦,为减少耀斑和痛风石提供真正的解决方案。
叶立天
联合创始人兼首席执行官